Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Windtree Therapeutics Inc (WINT)

Windtree Therapeutics Inc (WINT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,709
  • Shares Outstanding, K 34,188
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,790 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 0.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.77
  • Most Recent Earnings $-1.08 on 11/19/25
  • Next Earnings Date 04/21/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0410 +5.85%
on 11/26/25
0.0700 -38.00%
on 11/17/25
-0.0216 (-33.23%)
since 11/14/25
3-Month
0.0410 +5.85%
on 11/26/25
0.1900 -77.16%
on 10/13/25
-0.0396 (-47.71%)
since 09/16/25
52-Week
0.0410 +5.85%
on 11/26/25
19.7600 -99.78%
on 01/02/25
-19.7016 (-99.78%)
since 12/16/24

Most Recent Stories

More News
Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space

Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans...

WINT : 0.0434 (-13.20%)
Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The...

WINT : 0.0434 (-13.20%)
Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute...

WINT : 0.0434 (-13.20%)
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company

Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree...

WINT : 0.0434 (-13.20%)
Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation...

WINT : 0.0434 (-13.20%)
$250 Billion Stablecoin Surge: Corporate America's Crypto Treasury Revolution Accelerates

Issued on behalf of CEA Industries, Inc. VANCOUVER – Baystreet.ca News Commentary – Stablecoins are set to reshape the multitrillion-dollar U.S. Treasury market as Wall Street's explosive adoption...

^ETHUSD : 2,923.482 (-0.95%)
JFBR : 1.2300 (+10.81%)
WINT : 0.0434 (-13.20%)
WULF : 12.99 (+4.00%)
BMNR : 31.39 (+1.42%)
BNC : 6.42 (-0.47%)
BNC.TO : 34.64 (+0.46%)
^BTCUSDT : 86,723.66 (-1.19%)
^BTCUSD : 86,706.26 (-1.22%)
^ETHUSDT : 2,923.837 (-0.94%)
^ETHBTC : 0.033706 (+0.23%)
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30%...

WINT : 0.0434 (-13.20%)
Is the BNB Crypto a Buy Near Record Highs?

BNB is seeing an increase in institutional adoption, and this has pushed it to near record highs. Should you buy it here?

MSTR : 167.50 (+3.34%)
WINT : 0.0434 (-13.20%)
^ETHUSD : 2,923.482 (-0.95%)
NA : 3.01 (unch)
BNC : 6.42 (-0.47%)
VAPE : 17.77 (+1.95%)
^SOLUSDT : 126.5173 (-1.58%)
^BNBUSD : 857.510 (-1.70%)
^BTCUSD : 86,706.26 (-1.22%)
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous...

WINT : 0.0434 (-13.20%)
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in...

WINT : 0.0434 (-13.20%)

Business Summary

Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous...

See More

Key Turning Points

3rd Resistance Point 0.0612
2nd Resistance Point 0.0576
1st Resistance Point 0.0505
Last Price 0.0434
1st Support Level 0.0398
2nd Support Level 0.0362
3rd Support Level 0.0291

See More

52-Week High 19.7600
Fibonacci 61.8% 12.2273
Fibonacci 50% 9.9005
Fibonacci 38.2% 7.5737
Last Price 0.0434
52-Week Low 0.0410

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar